Interpace Diagnostics Presents Important Data at the World Congress of Gastroenterology at American College of Gastroenterolo...
23 October 2017 - 11:45PM
Interpace Diagnostics Group (NASDAQ:IDXG), a fully integrated
commercial company that provides clinically useful molecular
diagnostic tests and pathology services for improved patient
diagnosis and management, reported today that two publications were
presented at the World Congress of Gastroenterology (WCOG) American
College of Gastroenterology (ACG) 2017 Conference held October
16-18, 2017 in Orlando, Florida.
Dr. Mohammad Al-Haddad from the Department of Medicine at
Indiana University Hospital in Indianapolis, Indiana, and Dr. Nadim
Haddad, the Chief of the Division of Gastroenterology and
Hepatology at MedStar Georgetown University Hospital, Washington,
D.C., presented a study entitled “Long-Term Risk of Surgery and
Cancer in Patients Meeting AGA 2015 and Fukuoka 2012 Management
Criteria for Pancreatic Cystic Lesions.” The study demonstrated
that when PancraGEN® is used in a real world clinical setting,
molecular results helped determine cancer risk in patients with
pancreatic cysts that were worrisome but not definitively
malignant. Importantly, the study showed that high risk molecular
results increased necessary surgical resections of worrisome cysts
by over 40%. Low-risk molecular results reduced unnecessary
surgical resections of worrisome cysts by approximately 10%.
Dr. William Lyday of Gastroenterology Atlanta, LLC, formerly
with Cancer Treatment Centers of America, presented a study
entitled, “Regenerated Squamous Epithelium Following Radiofrequency
Ablation Manifests Molecular Alterations Present in the Pretreated
Barrett’s Mucosa.” The study demonstrated that patients who
undergo successful ablation treatment for Barrett’s Esophagus can
have residual genomic mutations that linger; they can even develop
new mutations that were not detectable prior to ablation. The
results position BarreGEN®, Interpace’s molecular test for
Barrett’s Esophagus, as a potential predictive biomarker that can
help guide patient management after successful ablation treatment
has taken place in patients with Barrett’s disease.
“These publications, shared with the significant number of other
physicians attending this prestigious conference, provided an
opportunity for a broader understanding of the potential benefit
that both PancraGEN and BarreGEN have for favorably impacting the
diagnosis and treatment of patients with complicated
gastroesophageal diseases such as pancreatic and esophageal
cancer,” stated Jack Stover, President and CEO of Interpace.
About PancraGEN
PancraGEN® is a pancreatic cyst molecular test
that, by using a small sample of pancreatic cyst fluid, can aid in
pancreatic cancer risk assessment. PancraGEN® is
90% accurate, according to clinical studies, enabling effective
risk stratification of patients. Pancreatic cancer is often
difficult to diagnose in early stages and typically spreads rapidly
with signs and symptoms appearing when the cancer is significantly
advanced. Because of this, and that complete surgical removal of
the pancreas is not possible, pancreatic cancer is considered a
leading cause of cancer deaths.
About BarreGEN
Interpace Diagnostics' BarreGEN test utilizes the PathFinderTG®
platform, which assesses loss of heterozygosity and microsatellite
instability mutations of multiple tumor suppressor genes. BarreGEN
summarizes this genomic instability information as the Mutational
Load, enabling physicians to more accurately stratify patients with
Barrett's esophagus for risk of progression to dysplasia and
cancer. This can allow for more personalized management of the
disease, including early intervention to decrease likelihood of the
progression to cancer. All patients with Barrett's esophagus
or those that have had radiofrequency ablation are potential
candidates for testing with BarreGEN.
About the American College of Gastroenterology and
ACG
The American College of Gastroenterology is one of the largest
specialty societies focused on diseases of the gastrointestinal
tract. The College sponsors numerous educational meetings
throughout the year for their members, including the Annual
meeting, which brings together over 5,000 Gastroenterologists and
other healthcare professionals to focus on diagnosing and treating
a wide array of GI related illnesses.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial
company that provides clinically useful molecular diagnostic tests
and pathology services for evaluating risk of cancer by leveraging
the latest technology in personalized medicine for better patient
diagnosis and management. The Company currently has four
commercialized molecular tests; PancraGEN® for the diagnosis and
prognosis of pancreatic cancer; ThyGenX, for the diagnosis of
thyroid cancer from thyroid nodules utilizing a next generation
sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer
utilizing a proprietary gene expression assay and MVPdX™, a test
that differentiates local recurrence of cancer versus new primary
cancer formation. Interpace Diagnostics' mission is to
provide personalized medicine through molecular diagnostics and
innovation to advance patient care based on rigorous science.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, relating to the Company's
future financial and operating performance. The Company has
attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, the Company's ability to adequately finance the
business, its ability to restructure its liabilities and other
obligations, the market's acceptance of its molecular diagnostic
tests, its ability to retain or secure reimbursement, its ability
to secure additional business and generate higher profit margins
through sales of its molecular diagnostic tests, in-licensing or
other means, projections of future revenues, growth, gross profit
and anticipated internal rate of return on investments and its
ability to maintain its NASDAQ listing. Additionally, all
forward-looking statements are subject to the “Risk Factors”
detailed from time to time in the Company's most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q.
Because of these and other risks, uncertainties and assumptions,
undue reliance should not be placed on these forward-looking
statements. In addition, these statements speak only as of the date
of this press release and, except as may be required by law, the
Company undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:
Interpace DiagnosticsInvestor Relations:Paul
KuntzRedChippaul@redchip.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2024 to May 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From May 2023 to May 2024